Core Viewpoint - Sharp Therapeutics Corp. is raising a minimum of US$10,000,000 through a non-brokered private placement, with shares priced at no less than US$2.50 each, expected to close in Q1 2026 [1] Group 1: Private Placement Details - The private placement will consist of common shares priced at not less than US$2.50 per share, with the offering expected to close in the first quarter of 2026 [1] - STX Partners, Sharp's largest shareholder, has committed to purchase at least 1,600,000 shares for approximately US$4,000,000, contingent upon the company raising at least US$6,000,000 from other investors [2] - The insider participation in the offering is classified as a related-party transaction, exempt from formal evaluation or minority shareholder approval under MI 61-101 [3] Group 2: Company Progress and Future Plans - Sharp is advancing its '901 candidate for Phase I trials in Gaucher disease, with STX's increased investment allowing the company to focus on generating key data supporting the treatment's effectiveness [4] - The company has made progress in its GBA1-Gaucher program, with pre-IND studies indicating that the '901 compound is well tolerated at higher doses, suggesting potential as a front-line therapy [5] - Sharp plans to file for Orphan Drug Designation for '901 with the US FDA in Q1 2026 [5] Group 3: Stock Options - The company granted 200,000 stock options to certain directors at an exercise price of CAD$1.48/US$1.07, with a 3-year vesting provision [6] - An additional 225,000 options were granted to an officer at an exercise price of CAD$2.21/US$1.60, also subject to a 3-year vesting provision [7] Group 4: Company Overview - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies [8]

Core Points - Sharp Therapeutics Corp. is arranging a non-brokered private placement to raise at least US$10,000,000, with shares priced at a minimum of US$2.50 each, expected to close in Q4 2025 [1] - STX Partners, Sharp's largest shareholder, has committed to purchase at least 1,200,000 shares for approximately US$3,000,000, contingent on the company raising at least US$7,000,000 from other investors [2] - The insider participation in the offering is classified as a related-party transaction, exempt from formal evaluation or minority shareholder approval under Multilateral Instrument 61-101 [3] Company Insights - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing high throughput screening technologies and computationally optimized compound libraries [6] - The company aims to produce small molecule compounds that restore activity in mutated proteins, potentially allowing for treatment of genetic disorders with conventional pill-based medicines [6] Management Statements - John Hathaway, managing partner of STX, expressed excitement about continuing investment in Sharp and highlighted the scientific progress, particularly regarding the Gaucher development candidate [4] - Scott Sneddon, CEO of Sharp, noted the significance of STX's commitment in supporting the company's Phase I trials for its candidate '901, an oral treatment for Gaucher disease and other lysosomal storage disorders [4]